S5-E11.1 – How the Rezdiffra Approval Has Affected How One Clinic Manages MASH Patients
Michael Charlton describes the impact of Rezdiffra on practices and procedures in his clinic
April 19, 2024
Michael Charlton describes the impact of Rezdiffra on practices and procedures in his clinic
Michael Charlton joins the Surfers for a far-reaching conversation, with topics ranging from how his clinic is integrating Rezdiffra in MASH patient treatment to exciting research, both reported and in development.
Hannes Hagstrom and the Surfers consider how the need for predictive biomarkers will co-evolve with in-office screening as multiple drugs come to market.
Hannes Hagstrom joins the Surfers to explore the ways that increased access to and awareness of VCTE or other in-office scanning will improve MASLD therapy.
Hannes Hagstrom join the Surfers in discussing studies that demonstrate the value of different nutritional approaches in driving improved liver health.
Hannes Hagstrom joins the Surfers to discuss recent studies focused on VCTE. , both in its prognostic capability for MASLD patients when compared to biopsy and separately as a therapeutic agent.
Hannes Hagstrom joins the Surfers to discuss the value of VCTE or other in-office MASLD monitoring due to the results providing prognoses comparable or superior to biopsy and feedback for patient self-management.
Patient advocates, led by GLI’s Jeff McIntyre, discuss advocates’ goals for a MASH drug label and the steps they took to communicate this information to FDA.
Last Thursday, March 14, Rezdiffra (resmetirom) became the first drug approved in the US for MASH. Five leading North American MASLD patient advocates join the Surfers to discuss their feelings about this approval along with the opportunities and challenges that lie ahead.
The launch of Rezdiffra raises this pivotal question: which MASH patients are the correct initial targets for the first MASH drug?